NCT05184400 (CHOCA) is a clinical trial in Biliary Tract Cancer, sponsored by Herlev and Gentofte Hospital.

Who is sponsoring NCT05184400?

NCT05184400 is sponsored by Herlev and Gentofte Hospital.

What condition does NCT05184400 study?

NCT05184400 studies Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer.

Is NCT05184400 still recruiting?

NCT05184400 is currently recruiting now. Last updated 11 January 2022.

Last reviewed 2022-01-11 · How we verify

NCT05184400: CHOCA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer

Recruiting now Last updated 11 January 2022

What this trial tests

trial in Biliary Tract Cancer in 500 participants. Currently enrolling.

Timeline

1 January 2015

Primary endpoint
31 December 2030

31 December 2030

Quick facts

Lead sponsor	Herlev and Gentofte Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 January 2015
Primary completion	31 December 2030
Estimated completion	31 December 2030
Sites	1 location across Denmark

Conditions studied

Biliary Tract Cancer — all drugs for Biliary Tract Cancer →
Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
Gallbladder Cancer — all drugs for Gallbladder Cancer →

Sponsor

Herlev and Gentofte Hospital

Who can join

18 and older, any sex, with Biliary Tract Cancer or Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

No validated biomarkers exist that can identify patients with biliary tract cancer at an early stage or predict treatment outcomes. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Protein Signatures and Individual Circulating Proteins, including IL-6 and IL-15, Associated with Prognosis in Patients with Biliary Tract Cancer.
Christensen TD, Madsen K, Maag E, Larsen O, et al · · 2023 · cited 7× · PMID 36831406 · DOI 10.3390/cancers15041062

Verify or expand the search:

Other recruiting trials for Biliary Tract Cancer

Currently open trials in the same condition.

NCT07221253 — A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Bili · Phase 3 · recruiting
NCT06529718 — Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients · Phase 2 · recruiting
NCT07151118 — ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer · recruiting
NCT07142226 — Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC · recruiting
NCT07135544 — A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initial · Phase 2 · recruiting

Other Herlev and Gentofte Hospital trials

Trials by the same sponsor.

NCT07493590 — CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction · not yet recruiting
NCT07321964 — The Effect of a Digital MediYoga Program on Quality of Life, Blood Pressure and Heart Rate Among Patients With Atrial Fi · NA · recruiting
NCT06706661 — Implementation of Nutritional Efforts on Discharged Older Patients · NA · recruiting
NCT06618417 — Evaluating the Impact of Home-Based Sleep Apnea Diagnostic on Well-Being, Health Behavior, and AF Load in Patients with · NA · recruiting
NCT06642272 — A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Hea · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05184400 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Herlev and Gentofte Hospital
Last refreshed: 11 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05184400.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing